Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dopaminergic Modulation of Belief Salience (MOBS)
NCT03754062Phase 1Completed
- Sponsor
- King's College London
- Start
- Jun 2017
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of haloperidol and levodopa in psychosis and schizophrenia, sponsored by King's College London. Primary endpoint: Beliefs and Values Inventory at 12 months. Started Jun 2017; status: completed.
02
Drugs
haloperidollevodopa
03
Conditions
psychosisschizophrenia
Beyond the preview
Go deeper on NCT03754062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03754062.